The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

St. Jude receives $2 million pledge from InfinityQS International Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ST. JUDE CHILDREN’S RESEARCH HOSPITAL received a pledge of $2 million over the next 10 years from InfinityQS International Inc.

St. Jude has named the Large Auditorium Gathering Space in the Marlo Thomas Center for Global Education and Collaboration in honor of InfinityQS to commemorate the company’s support.

InfinityQS received the Cardinal Stritch Donor of the Year Award, which recognizes a donor whose commitment reflects the vision and leadership of St. Jude founder Danny Thomas’ spiritual mentor, Samuel Cardinal Stritch, the Catholic archbishop of Chicago. InfinityQS has also sponsored and participated as St. Jude Heroes in three of the hospital’s annual St. Jude Memphis Marathon Weekend fundraisers.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account